BlackRock’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-75,753
| Closed | -$25K | – | 5668 |
|
|
2023
Q1 | $25K | Sell |
75,753
-145
| -0.2% | -$134 | ﹤0.01% | 5226 |
|
|
2022
Q4 | $54.6K | Sell |
75,898
-185
| -0.2% | -$183 | ﹤0.01% | 5205 |
|
|
2022
Q3 | $92K | Sell |
76,083
-287
| -0.4% | -$366 | ﹤0.01% | 5201 |
|
|
2022
Q2 | $91K | Buy |
76,370
+848
| +1% | +$1.28K | ﹤0.01% | 5262 |
|
|
2022
Q1 | $163K | Buy |
75,522
+135
| +0.2% | +$219 | ﹤0.01% | 5164 |
|
|
2021
Q4 | $113K | Buy |
75,387
+299
| +0.4% | +$602 | ﹤0.01% | 5242 |
|
|
2021
Q3 | $219K | Buy |
75,088
+319
| +0.4% | +$973 | ﹤0.01% | 4966 |
|
|
2021
Q2 | $247K | Sell |
74,769
-30,854
| -29% | -$99K | ﹤0.01% | 4855 |
|
|
2021
Q1 | $397K | Buy |
105,623
+2,173
| +2% | +$9.45K | ﹤0.01% | 4640 |
|
|
2020
Q4 | $366K | Buy |
103,450
+887
| +0.9% | +$3.74K | ﹤0.01% | 4392 |
|
|
2020
Q3 | $674K | Sell |
102,563
-1,181
| -1% | -$8.01K | ﹤0.01% | 4208 |
|
|
2020
Q2 | $772K | Buy |
103,744
+2,971
| +3% | +$20.2K | ﹤0.01% | 4113 |
|
|
2020
Q1 | $474K | Sell |
100,773
-11
| -0% | -$118 | ﹤0.01% | 4068 |
|
|
2019
Q4 | $1.3M | Sell |
100,784
-39
| -0% | -$360 | ﹤0.01% | 3921 |
|
|
2019
Q3 | $1.06M | Sell |
100,823
-25,767
| -20% | -$337K | ﹤0.01% | 3957 |
|
|
2019
Q2 | $2.15M | Sell |
126,590
-160,835
| -56% | -$4.35M | ﹤0.01% | 3756 |
|
|
2019
Q1 | $9.69M | Sell |
287,425
-6,126
| -2% | -$205K | ﹤0.01% | 3127 |
|
|
2018
Q4 | $8.57M | Sell |
293,551
-49,568
| -14% | -$2.2M | ﹤0.01% | 3172 |
|
|
2018
Q3 | $21.1M | Buy |
343,119
+31,880
| +10% | +$2.16M | ﹤0.01% | 2843 |
|
|
2018
Q2 | $23M | Buy |
311,239
+84,920
| +38% | +$6.62M | ﹤0.01% | 2779 |
|
|
2018
Q1 | $14.8M | Sell |
226,319
-5,098
| -2% | -$385K | ﹤0.01% | 2921 |
|
|
2017
Q4 | $19.5M | Sell |
231,417
-3,659
| -2% | -$359K | ﹤0.01% | 2797 |
|
|
2017
Q3 | $27.2M | Buy |
235,076
+14,925
| +7% | +$1.57M | ﹤0.01% | 2630 |
|
|
2017
Q2 | $25.7M | Buy |
220,151
+53,075
| +32% | +$6.59M | ﹤0.01% | 2655 |
|
|
2017
Q1 | $20.6M | Buy |
167,076
+166,819
| +64,910% | +$21.9M | ﹤0.01% | 2743 |
|
|
2016
Q4 | $35K | Buy |
257
+18
| +8% | +$3.2K | ﹤0.01% | 3086 |
|
|
2016
Q3 | $47K | Buy |
239
+29
| +14% | +$4.99K | ﹤0.01% | 2990 |
|
|
2016
Q2 | $28K | Buy |
210
+178
| +556% | +$19.8K | ﹤0.01% | 3167 |
|
|
2016
Q1 | $3K | Buy |
32
+11
| +52% | +$1.2K | ﹤0.01% | 3428 |
|
|
2015
Q4 | $4K | Sell |
21
-160
| -88% | -$28.6K | ﹤0.01% | 3215 |
|
|
2015
Q3 | $26K | Buy |
181
+160
| +762% | +$29.4K | ﹤0.01% | 2237 |
|
|
2015
Q2 | $4K | Hold |
21
| – | – | ﹤0.01% | 3168 |
|
|
2015
Q1 | $5K | Buy |
+21
| New | +$5.08K | ﹤0.01% | 3037 |
|
Other funds holding BLCM
BC
BRWA
TCM
PGAM
BlackRock's BLCM Position: Q2 2023 in Review
BlackRock sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2023, closing a stake of 75,753 shares — an estimated $25K sold.
BlackRock first reported a position in BLCM in Q1 2015 and held it in 33 quarters. The position peaked at $27.2M in Q3 2017. 4 funds tracked by Wall St. Rank hold BLCM as of Q2 2023.
- BlackRock reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
- BlackRock sold 75,753 Bellicum Pharmaceuticals, Inc. shares in Q2 2023, an estimated $25K.
- BlackRock first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2015 and held it in 33 quarters.
- BlackRock's Bellicum Pharmaceuticals, Inc. position peaked at $27.2M in Q3 2017.
- 4 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2023.
Based on BlackRock's 13F filing for Q2 2023, filed 11 Aug 2023.